HK Stock Price Fluctuated | Hualing Pharmaceutical (02552) rises over 10%. The company brings the important product Dapagliflozin tablets to participate in the 2023 national medical insurance negotiation.

"Hualing Pharmaceuticals (02552) rose more than 9%, up 10.11% at the time of writing, reporting a price of HKD 2.07 with a turnover of HKD 5.38 million. In terms of news, on the 18th at the 2023 National Medical Insurance negotiation site, it was noticed that the representative of Hualing Pharmaceuticals was "called out" by the staff of the negotiation site at around 14:14 and entered the negotiation room on the second floor for negotiation. However, as of now, one hour later, the journalist has not seen the representative of Hualing Enterprises coming down from the main staircase, which may mean that the negotiation has not yet ended. It is understood that Hualing Pharmaceuticals, as a biotech company that has just achieved the commercialization of its first product, is only involved in negotiations for one drug this year, namely Dugiratin. This drug is a glucose kinase activator developed by Hualing Pharmaceuticals after introduction and is the world's first approved GKA drug. Hualing Pharmaceuticals has high expectations for the rapid increase in output of this new diabetes drug after it enters medical insurance."